Conference Abstract

Measuring quality, equity, outcomes and efficiency in pharmaceutical care as a part of managed care

Tomasz Hermanowski, PhD, Professor, Head of Department of Pharmacoeconomics; InterQuality Project Leader, Medical University of Warsaw, Poland

Chris L. Pashos, PhD, United BioSource Corporation, Lexington, MA, USA

Sylwia I. Szafraniec-Burylo, MD, PhD, Department -Centre for Monitoring and Analyses of Population Health Status and Health Care System, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland

Aleksandra N. Krancberg, MSc, Medical University of Warsaw, Poland

Marta Kowalczyk, MSc, Medical University of Warsaw, Poland

Malgorzata Chmielewska, MSc, Medical University of Warsaw, Poland

Marcin Czech, MD, PhD, Associate Professor, Department of Pharmacoeconomics, Medical University of Warsaw, Poland

Correspondence to: Tomasz Hermanowski, PhD, Professor, Head of Department of Pharmacoeconomics; InterQuality Project Leader, Medical University of Warsaw, E-mail: tomasz.hermanowski@wum.edu.pl

Abstract:

The abstract presents results of the “InterQuality Project – International Research Project on Financing Quality in Healthcare” funded by the 7th Framework Programme (FP7) for Research and Technological Development of the European Union.

Grant Agreement No: HEALTH-F3-2010-261369

Objectives: To identify, classify and assess indicators reflecting outcomes, efficiency, quality and equity of pharmaceutical care services from the perspective of three stakeholders: healthcare professionals, patients and payers as well as to describe them in accordance with Donabedian’s [1] and ECHO [2] models.

Theory: Providing guidance for authorities seeking scientifically validated knowledge in the area of pharmaceutical care as a part of managed care is needed.

Methods: A systematic review restricted to the last 10 years was conducted in Medline, Embase and the Cochrane Library. A non-systematic review was added.

Results: 87 articles were identified during the systematic review and 10 publications were manually added. Indicators were assigned according to topic (efficiency, outcomes, quality and
equity), according to Donabedian's model [1] as structure, process and outcomes indicators and
to ECHO model [2] as clinical intermediary, clinical outcomes, humanistic intermediary,
humanistic and economic outcomes.

**Discussion:** The indicators that are probably most useful for population-wide decision making are
generic ones, as they allow comparisons between interventions. However, specific indicators are
also sensible as they are more responsive to changes caused by interventions, and thus allow
those changes to be measured.

**Conclusions:** Our work provides a comprehensive overview and new classification of indicators
ready to use for decision makers to help identify areas of outstanding quality in the area of
pharmaceutical care.

**Keywords**

indicators, outcomes, efficiency, quality, equity, pharmaceutical

**References**

2. Kozma CM, Reeder CE, Schulz RM. Economic, clinical and humanistic outcomes: a planning
model for pharmacoconomic research. Clinical Therapeutics 1993 Nov-Dec 15;6:121-32. Discussion
1120.

**Presentation** available at [http://www.integratedcarefoundation.org/content/13-managed-care](http://www.integratedcarefoundation.org/content/13-managed-care)